INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,467,000 | -18.5% | 31,532 | 0.0% | 0.01% | -12.5% |
| Q2 2022 | $1,800,000 | -94.8% | 31,532 | -94.5% | 0.02% | -93.7% |
| Q1 2022 | $34,806,000 | +15.7% | 568,811 | -1.1% | 0.25% | +18.1% |
| Q4 2021 | $30,094,000 | +38.0% | 574,978 | -1.7% | 0.22% | +30.3% |
| Q3 2021 | $21,812,000 | +173.2% | 585,074 | +199.2% | 0.16% | +179.7% |
| Q2 2021 | $7,983,000 | +267.2% | 195,560 | +198.0% | 0.06% | +293.3% |
| Q4 2019 | $2,174,000 | +405.6% | 65,619 | +14.0% | 0.02% | +400.0% |
| Q3 2019 | $430,000 | -53.3% | 57,557 | -18.8% | 0.00% | -50.0% |
| Q2 2019 | $920,000 | +77.6% | 70,869 | +66.9% | 0.01% | +50.0% |
| Q1 2019 | $518,000 | – | 42,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |